talaumidin
a neolignan from Aristolochia arcuata; structure in first source
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Abrantes, Marta:
1 article
(02/2010)
|
2. | Duarte, Noélia:
1 article
(02/2010)
|
3. | Ferreira, Maria-José U:
1 article
(02/2010)
|
4. | Molnar, Joseph:
1 article
(02/2010)
|
5. | Pusztai, Rozália:
1 article
(02/2010)
|
6. | Serly, Julianna:
1 article
(02/2010)
|
7. | Sherly, Julia:
1 article
(02/2010)
|
8. | Fukuyama, Yoshiyasu:
1 article
(07/2004)
|
9. | Mitsumoto, Yasuhide:
1 article
(07/2004)
|
10. | Nakatsukasa, Mika:
1 article
(07/2004)
|
Related Diseases
1. | Neurodegenerative Diseases (Neurodegenerative Disease)
|
2. | Lung Neoplasms (Lung Cancer)
02/01/2010
- " The lignans threo-4,4'-dihydroxy-3-methoxylignan, (-)-dihydroguaiaretic acid, 4'-hydroxy-3,3',4-trimethoxylignan, 3,3',4,4'-tetramethoxylignan, 4,4'-diacetyl-3,3'-dimethoxylignan, talaumidin, heliobuphthalmin, (-)-dihydro-cubebin, and hinokinin were evaluated for their ability to inhibit human cytomegalovirus (HCMV) IE-antigen expression in lung cancer cells (A549). "
|
|
Related Drugs and Biologics